Skip to content

MEDIFAR

Active Public limited companyfounded 1996active for 30 yearsBeerstraat 16, 2450 MeerhoutKBO/BCE: BE 0456.978.480 #3 company by equity in Meerhout, Wholesale and retail trade sector

Lifetime

20 annual accounts with figures on one time axis, 30 filings since 1996
peak of €267,216 in 2016
€247,744▲ 21.7%
peak of €115,474 in 2025
€115,474▲ 53.7%
peak of €950,588 in 2016
€869,111▼ 3.4%
€52,744▲ 16.3%
peak of 2.1 FTE in 2006
0.7 FTE▲ 40.0%
Board4 names since 1996
4 directors and 3 others
Documentsfilings and deeds
08-06-202653 days before the deadline
2025abbreviated format
Gross margin from €203,547 to €247,744Result from €75,116 to €115,474Staff from 0.5 FTE to 0.7 FTEDividend €146,115Debts from €45,333 to €52,744Cash from €208,315 to €333,678

Key points

from the 2025 annual accounts

Equity

€869,111 ▼ 3.4%
899,7522024+115,474Profit-146,115Dividend869,1112025

MEDIFAR paid out €146,115 in dividends. That is 127% of the 2025 profit.

Filings

30 annual accounts since 1996
AprilJune31 JulyOctober200020102020

The 2019 accounts came 13 days late. The other nine of the last ten were filed on time.

Position in the sector

94.3%

Higher solvency than 95% of companies in retail trade. The sector median is 36.8%, over 13,303 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 31,390 companies had the same profile as MEDIFAR has now. Each dot stands for 79 companies, two years later.

93.4%
were still trading
6.0%
stopped another way
0.5%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 31,390 companies, not a prediction for MEDIFAR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Managing director
Director, since 03-01-1996
Director, , since 26-06-2018
Director, , since 01-04-2024
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0456978480
1 director appointed, 2 reappointments (director and managing director) and (director) reappointed · appointed as director · and act as permanent representatives · General meeting of 23-05-2024 · Gazette deed
appointed as director acts as permanent representative · General meeting of 26-06-2018 · Gazette deed
Capital decrease of €589,500 to €62,000 The capital fell from €651,500 to €62,000 · General meeting of 27-12-2017 · Gazette deed
All 44 events

Comparable companies

same main activity, similar in size and age
Company
MEDIFAR Meerhout €0.9m €247,744 94.3% 0.7
FARMA WAELPUT Beveren-Kruibeke-Zwijndrecht €1.0m €258,723 82.3% 0.9
APOTHEEK PELGRIMS Hulshout €0.9m €281,286 50.0% 0.7
APOTHEEK ANNAERT - STORME Mechelen €0.9m €234,973 22.0% 0.9
APOTHEEK KEYMOLEN Vilvoorde €0.9m €283,013 47.8% 0.9
APOTHEEK ANN BOURGEOIS Aalst €1.0m €212,660 85.3% 0.8
Apotheek DELNAT Tongeren-Borgloon €1.0m €210,617 40.6% 0.7

These companies have the same main activity as MEDIFAR: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €870,000 and €1m, founded between 1987 and 2000.

Official details

Source: KBO
Status
Active since 03-01-1996Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730and 2 others
Joint committee
313Pharmacies and pricing offices · annual accounts 2021
Establishment unit
2.075.363.0052450 Meerhout, since 23-02-1996
Financial year end
31 December
Peppol
Reachable since 09-01-2025
Company details

Annual accounts 2025

≈ €1.2mestimated
€921,854▼ 2.5%
Employeeson 31-12-2025
2▲ 100%
Filing
Filed on 08-06-2026, 53 days before the end of the filing period
Financials

Insights on MEDIFAR

MEDIFAR files the abbreviated format. That format states no turnover. The gross margin rose from €217,647 in 2006 to €247,744 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about MEDIFAR

What is the company number of MEDIFAR?
The company number of MEDIFAR is 0456.978.480. The VAT number is the same number with BE in front: BE 0456.978.480.
Where is MEDIFAR based?
The registered office is at Beerstraat 16, 2450 Meerhout.Company details
What does MEDIFAR do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of MEDIFAR?
MEDIFAR is a public limited company (NV).
When was MEDIFAR founded?
MEDIFAR was founded on 03-01-1996.
Is MEDIFAR still active?
Yes, MEDIFAR is an active enterprise in the KBO register.
How many employees does MEDIFAR have?
MEDIFAR had an average of 0.7 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does MEDIFAR fall under?
In its 2021 annual accounts, MEDIFAR states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of MEDIFAR?
The turnover in financial year 2025 is about €1.2m. This figure is estimated from the gross margin of €247,744 and 43 comparable companies (NACE 477). It probably lies between €760,000 and €2.4m.
Is MEDIFAR profitable?
In financial year 2025, MEDIFAR made a profit of €115,474.
Where can I find the annual accounts of MEDIFAR?
MEDIFAR filed 30 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of MEDIFAR due?
MEDIFAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.